Wright, K. D., Zimmerman, M. A., Fine, E., Aspri, T., Kieran, M. W., & Chi, S. (2018). LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY. Neuro Oncol.
Citação norma ChicagoWright, Karen D., Mary Ann Zimmerman, Elizabeth Fine, Tristan Aspri, Mark W. Kieran, and Susan Chi. "LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY." Neuro Oncol 2018.
Citação norma MLAWright, Karen D., et al. "LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY." Neuro Oncol 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.